Anteris’ DurAVR heart valve shows 1% heart failure hospitalization rate at one year in study
AVR•Anteris Technologies reported a 1% heart failure hospitalization rate and no valve-related deaths among 100 patients one year after receiving its DurAVR heart valve. All-cause mortality was 6%.
1. One-year results
Anteris Technologies announced one-year results for its DurAVR heart valve in 100 patients with severe aortic stenosis and small aortic annuli. Heart failure hospitalization was 1%, there were no valve-related deaths, and all-cause mortality was 6%. Patients showed substantial symptom improvement, with no moderate or severe leakage around the valve.
2. Pivotal trial
The results were presented at PCR London Valves on Nov. 22, 2026. The pivotal PARADIGM trial is enrolling patients in the United States and Europe to compare DurAVR with commercially available replacement valves.




